Advertisement

Cell-Internalization SELEX of RNA Aptamers as a Starting Point for Prostate Cancer Research

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 2174)

Abstract

In the treatment of cancer, over the last decade different drugs delivery systems have been developed to increase therapeutic specificity to improve drug’s efficacy, and safety by increasing bioavailability. Among these systems, small nucleic acid molecules with a three-dimensional structure, known as aptamers, have shown several advantages. Several approaches to design aptamers require modifications from starting libraries of DNA sequences. Here, we describe cell-internalization SELEX (Systematic Evolution of Ligands by Exponential Enrichment), a sophisticated technique based on RNA aptamers as a starting point, that enables design functional aptamers as drug-delivery tools. This variation of the original SELEX technique using RNA aptamers instead DNA aptamers allows to obtain aptamers that are internalized in prostate cancer cells using as a starting point an RNA aptamer library with 76 nucleotides. The major advantage of this technique is that modifications are not required in the initial library, as initial T7 transcription promoter or 2′F nucleotides before sequencing.

Key words

RNA aptamers Cell-internalization SELEX Prostate cancer Drug delivery systems 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Global Cancer Observatory, (IARC) (2018) Estimated number of new cases, worldwide, all cancers, men, all ages. http://gco.iarc.fr/
  2. 2.
    Wright JL, Lange PH (2007) Newer potential biomarkers in prostate cancer. Rev Urol 9(4):207–213PubMedPubMedCentralGoogle Scholar
  3. 3.
    Richiardi L, Fiano V, De Marco L, Vizzini L, Gillio-Tos A, Merletti F (2007) Promoter hypermethylation in APC, GSPT1 and RUNX3 and long-term mortality of prostate cancer patients. Cancer Res 67(9):14–18Google Scholar
  4. 4.
    Yang Z, Yu L, Wang Z (2016) PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 28(1):65–71PubMedPubMedCentralGoogle Scholar
  5. 5.
    Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J (2017) The use of biomarkers in prostate cancer screening and treatment. Rev Urol 19(4):221–234PubMedPubMedCentralGoogle Scholar
  6. 6.
    Liu M, Yu X, Chen Z, Yang T, Yang D, Liu Q et al (2017) Aptamer selection and applications for breast cancer diagnostics and therapy. J Nanobiotechnol 15(1):81CrossRefGoogle Scholar
  7. 7.
    Graham JC, Zarbl H (2012) Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLoS One 7(4):e36103PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ahmadyousefi Y, Malih S, Mirzaee Y, Saidijam M (2019) Nucleic acid aptamers in diagnosis of colorectal cancer. Biochimie 156:1–11PubMedCrossRefGoogle Scholar
  9. 9.
    Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y, Cardona D, Witek RP, Liu C, Tan W (2008) Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 80(3):721–728PubMedCrossRefGoogle Scholar
  10. 10.
    Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F et al (2018) Aptamer-miR-34c conjugate affects cell proliferation of non-small-cell lung cancer cells. Mol Ther Nucleic acids 13:334–346PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Poturnayová A, Buríková M, Bízik J, Hianik T (2019) DNA aptamers in the detection of leukemia cells by the thickness shear mode acoustics method. ChemPhysChem 20(4):545–554PubMedCrossRefGoogle Scholar
  12. 12.
    Aptekar S, Arora M, Lawrence C, Lea RW, Ashton K, Dawson T, Alder JE, Shaw L (2015) Selective targeting to glioma with nucleic acid aptamers. PLoS One 10(8):e0134957PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Germer K, Leonard M, Zhang X (2013) RNA aptamers and their therapeutic and diagnostic applications. Int J Biochem Mol Biol 4(1):27–40PubMedPubMedCentralGoogle Scholar
  14. 14.
    Duan M, Long Y, Yang C, Wu X, Sun Y, Li J et al (2016) Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging. Oncotarget 7(24):36436–36446PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Neves M, Slavkovic S, Churcher ZR, Johnson PE (2017) Salt-mediated two-site ligand binding by the cocaine-binding aptamer. Nucleic Acids Res 45(3):1041–1048PubMedGoogle Scholar
  16. 16.
    Deng B, Lin Y, Wang C, Li F, Wang Z, Zhang H, Li XF, Le XC (2014) Aptamer binding assays for proteins: the thrombin example—a review. Anal Chim Acta 837:1–15PubMedCrossRefGoogle Scholar
  17. 17.
    Jing Y, Cai M, Xu H, Zhou L, Yan Q, Gao J, Wang H (2018) Aptamer-recognized carbohydrates on the cell membrane revealed by super-resolution microscopy. Nanoscale 10(16):7457–7464PubMedCrossRefGoogle Scholar
  18. 18.
    Ohuchi S (2012) Cell-SELEX technology. Biores Open Access 1(6):265–272PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Percze K, Szakács Z, Scholz É, András J, Szeitner Z, Kieboom CH, Ferwerda G, Jonge MI, Gyurcsányi RE, Mészáros T (2017) Aptamers for respiratory syncytial virus detection. Sci Rep 7:42794PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hori S, Herrera A, Rossi JJ, Zhou J (2018) Current advances in aptamers for cancer diagnosis and therapy. Cancer 10(1):9CrossRefGoogle Scholar
  21. 21.
    McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E et al (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24(8):1005–1015PubMedCrossRefGoogle Scholar
  22. 22.
    Lupold SE (2018) Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey. Am J Clin Exp Urol 6(2):78–86PubMedPubMedCentralGoogle Scholar
  23. 23.
    Kruspe S, Giangrande PH (2017) Aptamer-siRNA chimeras: discovery, progress, and future prospects. Biomedicine 5(3):45Google Scholar
  24. 24.
    Baeka SE, Leea KH, Park YS, Oh D-K, Oh S et al (2014) RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J Control Release 196:234–242CrossRefGoogle Scholar
  25. 25.
    Chen Z, Tai Z, Gu F, Hu C, Zhu Q, Gao S (2016) Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. Eur J Pharm Biopharm 107:130–141PubMedCrossRefGoogle Scholar
  26. 26.
    Li B, Li C (2017) Suppression of prostate cancer metastasis by DPYSL3-targeted saRNA. Adv Exp Med Biol 983:207–216PubMedCrossRefGoogle Scholar
  27. 27.
    Hossain D, Bostwick DG (2013) Significance of the TMPRSS2:ERG gene fusion in prostate cancer. BJU Int 111(5):834–835PubMedCrossRefGoogle Scholar
  28. 28.
    Chai C, Xie Z, Grotewold E (2011) SELEX (systematic evolution of ligands by EXponential enrichment), as a powerful tool for deciphering the protein–DNA interaction space. Chapter 14. In: Yuan L, Perry SE (eds) Plant transcription factors. Methods in molecular biology. Springer Science+Bussiness Media, Berlin, p 754Google Scholar
  29. 29.
    Chen M, Yu Y, Jiang F, Zhou J, Li Y, Liang C et al (2016) Development of cell-SELEX technology and its application in cancer diagnosis and therapy. Int J Mol Sci 17(12):2079.  https://doi.org/10.3390/ijms17122079PubMedCentralCrossRefGoogle Scholar
  30. 30.
    Morris KN, Jensen KB, Julin CM, Weil M, Gold L (1998) High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 95(6):2902–2907PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Rong Y, Chen H, Zhou XF, Yin CQ, Wang BC, Peng CW, Liu SP et al (2016) Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers. Oncotarget 7(7):8282–8294PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Authors and Affiliations

  1. 1.Oncogenomics LaboratoryNational Institute of Genomic MedicineMexico CityMexico

Personalised recommendations

Cite protocol

Buy options